DC Field | Value | Language |
dc.contributor.author | Gureev, V. V. | - |
dc.contributor.author | Martynova, O. V. | - |
dc.contributor.author | Anciferova, O. E. | - |
dc.contributor.author | Martynov, M. A. | - |
dc.contributor.author | Pokrovskaia, T. G. | - |
dc.date.accessioned | 2021-07-02T13:05:25Z | - |
dc.date.available | 2021-07-02T13:05:25Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Correction of adma-induced preeclampsia with the use of phosphodiesterase 5 and selective inhibitor of arginase II ZB49-0010 / V. V. Gureev [et al.] // Научный результат. Сер. Медицина и фармация. - 2015. - Т.1, №4(6).-С. 66-68. - doi: 10.18413/2313-8955-2015-1-4-66-68. | ru |
dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/42753 | - |
dc.description.abstract | Simulation experimental ADMA-like preeclampsia was carried out by administering the rats with L-NAME during 14-20 days of pregnancy. In animals, there was an increase in blood pressure, proteinuria, impaired microcirculation in the placenta, the violation of the regulation of vascular tone and destructive changes in the ischemic placenta. The use of phosphodiesterase 5 and selective inhibitor of arginase II ZB49-0010 leads to the expression of morphological and functional correction of violations occurring in modeling of experimental preeclampsia | ru |
dc.language.iso | en | ru |
dc.subject | medicine | ru |
dc.subject | obstetrics | ru |
dc.subject | pathological obstetrics | ru |
dc.subject | pathology of pregnancy | ru |
dc.subject | pharmacology | ru |
dc.subject | N-nitro-L-arginine methyl ester | ru |
dc.subject | endothelial dysfunction | ru |
dc.subject | preeclampsia | ru |
dc.subject | phosphodiesterase 5 | ru |
dc.subject | selective inhibitor of arginase II | ru |
dc.subject | rats | ru |
dc.title | Correction of adma-induced preeclampsia with the use of phosphodiesterase 5 and selective inhibitor of arginase II ZB49-0010 | ru |
dc.type | Article | ru |
Appears in Collections: | Т. 1, вып. 4
|